S&P Futures
4,169.50 -6.25 (-0.15%) Dow Futures
34,165.00 -41.00 (-0.12%) Nasdaq Futures
12,757.25 -19.50 (-0.15%) Russell 2000 Futures
1,974.80 -4.50 (-0.23%) Crude Oil
77.22 +0.08 (+0.10%) Gold
1,887.70 +2.90 (+0.15%)
Karyopharm Therapeutics Inc. (KPTI)
After hours:
- Zacks
Analysts Estimate Karyopharm Therapeutics (KPTI) to Report a Decline in Earnings: What to Look Out for
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 113,250 restricted stock units (RSUs) to ten newly-hired employees. These RSU awards were granted as of January 31, 2023 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule
- PR Newswire
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2022 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2022 achievements and 2023 objectives.
